Ion channels and neurotransmitter receptors are the linchpin of brain function. They control neuronal membrane potential and excitability as well as synaptic transmission and neuronal communication [1] [2] [3] [4] . Neuronal ion channels and neurotransmitter receptors are involved in many neurological and psychiatric disorders, and are thus major drug targets; an analysis in 2011 showed that more than 40% of all then-commercialized drugs targeted an ion channel or a surface receptor 5 . Thus, there is enormous interest in understanding how these proteins work and are regulated, for better comprehension of brain function and for therapeutic purposes.
. Neuronal ion channels and neurotransmitter receptors are involved in many neurological and psychiatric disorders, and are thus major drug targets; an analysis in 2011 showed that more than 40% of all then-commercialized drugs targeted an ion channel or a surface receptor 5 . Thus, there is enormous interest in understanding how these proteins work and are regulated, for better comprehension of brain function and for therapeutic purposes.
Neuronal ion channels and receptors show great diversity, with each family comprising numerous members (or subtypes) with distinct distributions and properties. This heterogeneity largely derives from the multigenic and multimeric nature of these protein families, which results in a wide variety of subunit assemblies. As examples, 77 genes encode potassium channel subunits in humans, whereas 19 subunits encode pentameric GABA type A receptors (GABA A Rs), which mediate the bulk of synaptic inhibition 6, 7 . The physiological relevance of such plurality is largely unknown: whether individual ion channel or receptor subtypes carry out specific tasks or whether redundancy prevails. Hopefully this diversity can be exploited for new and better medicines. So far, research in electrophysiology, molecular biology, genetics, biochemistry, pharmacology and structural biology has provided much information on the structure and function of ion channels and receptors. However, none of these approaches combines the proper molecular and spatiotemporal levels of precision that are required for probing specific ion channel and receptor subpopulations in live systems. Consequently, there is great need for novel approaches to rapidly and precisely manipulate different brain proteins with high levels of control at the molecular, cellular and network levels.
Light permits superior spatiotemporal resolution and, in combination with genetic strategies and pharmacology, enables precise manipulation of protein targets with defined molecular compositions 8, 9 . Optogenetics has driven huge advances in our causal understanding of the neural circuits underlying behaviour, and it confers high temporal precision, on-off control of neuronal activity and cell-type specificity 10 . However, classical optogenetics lacks the ability to probe the role of specific receptors or signalling pathways in the control of physiology and behaviours. Optopharmacology (also known as photopharmacology, optochemical genetics or synthetic optogenetics) aims to fill this gap, by endowing light sensitivity to specific endogenous protein targets, and thus providing a molecular control and understanding of brain function.
Several photoreactive ligands were made in the 1970s [11] [12] [13] [14] , but in recent years the field of optopharmacology has boomed, with the development of new methods that directly tag 'blind' (that is, light-insensitive) proteins with light-sensitive protein modules or synthetic chromophores [15] [16] [17] [18] . Such photoactuators enable the manipulation and interrogation of target proteins, and even individual constitutive subunits, with unprecedented precision. Progress in optopharmacology has been particularly applicable and striking in neuro science, where conventional in vivo pharmacology displays many Optical control of neuronal ion channels and receptors inherent limitations (including slow diffusion, off-target effects, poor spatial confinement and slow reversibility). In this Review, we present current strategies to render neuronal receptors and ion channels responsive to light and the application of such strategies to biophysical and neurophysiological studies. Optopharmacology covers multiple scales, from the molecular, synaptic and cellular levels, up to the circuit level. We also discuss practicalities and challenges for in vivo implementation in behaving animals and translational potentialities in the clinic. Optopharmacological approaches are poised to illuminate our understanding of the molecular and functional diversity of key biomolecules in the nervous system, with important consequences for neuronal signalling in health and disease.
Optopharmacological approaches
Three main types of approach have been taken in the design of light-controllable receptors and ion channels ( Fig. 1) : chemical approaches, which rely exclusively on exogenous photosensitive chemicals (with no modification of target proteins); genetic approaches, which require genetic modification of the protein of interest; and hybrid approaches, which are two-component systems involving both genetic and chemical modifications. As we describe below and in Table 1 , each of these approaches has its own requirements, with concomitant advantages and limitations. Choosing the right tool depends on the biological question of interest and the amenability of the target to genetic modification. Together, they provide a large toolset for the precise manipulation of membrane proteins and their associated signalling pathways, with broad applicability in molecular and neuronal studies.
Chemical approaches
Photochemical approaches target native (that is, unmodified, wild-type) proteins and first emerged in the 1970s. The general idea is to confer light sensitivity to a freely diffusible ligand, rather than to a target protein. Chemists have developed various photochemicals for the control of neurotransmitter receptors and other signalling molecules, including caged compounds, photoswitches and photolabels (Fig. 1a) . Such chemical approaches have one crucial advantage: they bestow light sensitivity on endogenous proteins without requiring gene modification, and therefore act on native tissues and signalling molecules. However, they may lack precise specificity for their molecular target.
Caged compounds. Caged compounds contain a photoremovable protecting group that is cleaved upon light stimulation, resulting in a rapid release of biologically active molecules 15 . As such, the compound is inert (that is, caged) in darkness, whereas uncaging following illumination triggers a rapid increase in the concentration of the molecule. Diffusible caged ligands are arguably the most widely used photochemicals in neuroscience 15 . Several desirable properties of caged compounds explain their wide use 15, 19, 20 . They are inherently biologically inactive before photolysis, whereas full biological activity is recovered by irradiation. Their rate of uncaging is usually much faster than most biological processes that are being studied, and photolysis uses biocompatible wavelengths that are not absorbed by proteins or DNA. Finally, the chromophoric by-products are usually non-toxic. Most neurotransmitters have been caged, including glutamate [21] [22] [23] [24] , GABA [25] [26] [27] [28] [29] , dopamine 30 and serotonin 31 . Moreover, most of these have been made two-photon-sensitive, enabling manipulations at a fine spatial resolution, at the level of individual dendritic spines 32 . Caged molecules with refined pharmacological spectra have also been developed, including caged nicotinic receptor agonists [33] [34] [35] [36] , glycine receptor agonists 37 , caged NMDA 38, 39 and kainate 40 , and caged agonists and antagonists of neuropeptide receptors [41] [42] [43] , enabling the control of specific receptor types or subtypes.
Photoswitchable ligands. Photoswitchable ligands (also known as photochromic ligands) contain a photoisomerizing group that, unlike caged compounds, gives them the major advantage of alternating reversibly between an active and an inactive form with exposure to two different wavelengths of light 18, 44, 45 . This results in a reversible on-off control of protein targets. In some rare cases, photoswitchable ligands can covalently attach to an ideally positioned endogenous reactive amino acid on a target wild-type receptor or ion channel 11, 14, 46 . The use of two different colours of light to drive the active and inactive states of molecular photo switches means that the activation and deactivation (or inhibition and disinhibition) steps can be precisely timecontrolled 47 . Photoswitchable ligands have been designed for a huge variety of neurotransmitter receptors and ion channels 8, 17, 18, 48, 49 (Table 1) . Examples include blockers of voltage-gated K + channels 45, 50, 51 , Na + channels 52, 53 and Ca 2+ channels 54 . The most commonly used synthetic photoswitch is azobenzene (Fig. 2) . Azobenzenes have many advantageous attributes 73, 74 : they are small (length <10 Å) and easy to synthesize, display high quantum yield (0.2-0.5) and minimal photobleaching, and can be rapidly and reversibly switched between a bent, cis form and an extended, trans configuration using two different colours, classically near-ultraviolet (near-UV; 360-400 nm) and blue-green light (480-550 nm). Usually the trans form is the most stable isomer (in darkness or visible light), whereas the cis form gradually relaxes back to the trans configuration in darkness with kinetics ranging from milliseconds to days, depending on the chemical substituents 75 . 'Bridged' azobenzenes that have a two-carbon link between ortho-positions provide an exception, in that their cis configuration is thermodynamically favoured 76, 77 . Azobenzenes that have
Photo-isomerizing group a molecular group that can be switched between two distinct cis and trans configurations, or isomers, with particular wavelengths of light.
Allosteric modulators
Modulators of the activity of enzymes and receptors that target a ligand-binding site distinct from that to which the substrate or agonist binds.
Quantum yield
The efficiency of a photo chemical reaction with respect to the amount of light absorbed.
NATuRE REvIEwS | NeuROscieNce Photoswitchable tethered ligands can be covalently attached to receptors in two ways -either to a cysteinesubstituted site, usually through maleimide-sulfhydryl chemistry (as depicted), or to a self-labelling protein tag (not depicted) -in both cases resulting in reversible control of protein activity. In nanotweezers, a bis-maleimide photoswitch bridges two cysteine mutants. Light-induced conformational changes of the photosensitive moiety exert mechanical forces on the protein, potentially triggering its activation in the absence of a ligand. Note that caged compounds, photolabels and CALI are unidirectional, whereas photoswitches (both synthetic and natural) allow for bidirectionality.
www.nature.com/nrn slow relaxation lifetimes (on the order of hours) show excellent bistability without the need for long-duration exposure to light. Rather brief pulses of light are sufficient to rapidly toggle the azobenzene between its two states. To avoid UV irradiation and thus limit phototoxicity and enhance biocompatibility, red-shifted azobenzenes were recently developed 51, [78] [79] [80] [81] [82] [83] [84] . Red shifting usually comes at the expense of faster spontaneous cis-to-trans photorelaxation kinetics (on the order of milliseconds to seconds; but see reF. 85 ). Thus, whereas ideally one photo-isomer of the azobenzene would be fully pharmacologically inactive while the other is active, in practice both isomers are active to some extent (for diffusible photoswitches, at least), resulting in 10-fold to 100-fold maximal differences in activity between the two isomers (250-fold in reF.
86
). Moreover, since the absorption spectra of the two isomers overlap to some degree, the photostationary state ratio between the two isomers is classically around 95:5 (reFs 87, 88 ). Remarkably, many pharmacological agents can be converted into photoswitchable drugs by substituting a genuine azobenzene moiety for an azobenzene-related structural motif (termed azologization; reFs 65, 66, 74, 89 ). Other photochromic chemicals besides azobenzenes include the spiropyrans 90 and dithienylethenes 91 , but their use as photoswitches in biology remains limited.
Photo-affinity labels. Photo-affinity labels (PALs) contain a photoreactive group that is converted to a reactive, alkylating entity upon photostimulation. PALs reversibly bind to receptors in darkness but bind permanently after photoactivation; hence, they can 'trap' receptors or ligand-activated ion channels in a permanently activated (or inhibited) state [92] [93] [94] . PALs have been used with various neuronal ion channels and receptors, including cyclic-nucleotide gated channels 92 , GABA A receptors 94 , nAChRs 16 and AMPA receptors (AMPARs) 93 , as well as various G-protein-coupled receptors (GPCRs) 95 .
Chromophore-assisted laser inactivation. Chromophoreassisted laser inactivation (CALI) relies on a synthetic dye (such as malachite green, fluorescein or eosin) that releases short-lived reactive oxygen species upon photostimulation (mostly singlet oxygen), leading to damage and irreversible inactivation of nearby proteins through oxidation of amino acid side chains and protein crosslinking 96, 97 . CALI can be targeted to specific endogenous membrane proteins using antibodies, as demonstrated with AMPARs 98 .
Genetic approaches
Genetic approaches require the incorporation of a proteinbased light-sensitive module in the target protein, resulting in a light-responsive receptor or ion channel that is fully genetically encoded, without any exogenous cofactors. Genetic and hybrid approaches have one essential superiority over chemical approaches: they allow photosensitization with molecular and cellular specificitya crucial feature, when it comes to dissecting discrete signalling pathways in complex circuits.
Various natural photoreceptors from animals, plants and microorganisms have been fused to mammalian cytoplasmic signalling proteins and enzymes to render them photocontrollable 99 , but only in a few cases have they been fused to membrane receptors or ion channels. Natural photoreceptors include opsins, which contain an endogenous retinal photoswitch (Fig. 1b) , the lightoxygen-voltage (LOV)-sensing domains of flavoproteins, and cryptochromes (including crytochrome 2 (CRY2)), the latter two of which are from plants. Purely genetic methods are easier to use than hybrid approaches, especially in vivo, as light sensitivity is inherent to the protein itself with its natural cofactor (virtually any mammalian cell produces enough quantities of retinal or flavin photosensors).
Opsins. Opsins belong to the GPCR superfamily and can be engineered as chimeric receptors with intracellular loops of (light-insensitive) neuromodulatory GPCRs to produce light-controllable receptors (optoXRs) 100 . Although restricted to GPCRs, opto-XR engineering has proved highly versatile, enabling light control of signalling via adrenergic receptors [101] [102] [103] LOV and CRY2 domains. LOV domains contain a flavin mononucleotide chromophore, whereas CRY2 domains use a flavin adenine dinucleotide chromophore. Blue light triggers major conformational changes in these plant domains (Fig. 1b) -specifically, unfolding of the LOV domain and dimerization of CRY2 with CIB1 -that can be exploited to modulate protein-protein interactions and protein localization with subcellular precision 99 . These plant domains are relatively bulky protein modules (~12-19 kDa) with inherently slow on and off kinetics. Consequently, they have been used mostly to control slow cell processes, such as neurite outgrowth, intracellular signalling cascades, gene expression or protein localization, and less often to manipulate rapid signalling events, such as neurotransmission 113 . Ion channels can be indirectly photosensitized by fusing LOV domains to partner proteins such as K + channel toxins 114 or the intracellular Ca 2+ sensor protein stromal interaction molecule 1 (STIM1), which interacts with and activates Ca 2+ release-activated channels 115 . LOV domains can also be fused to GTPases, thereby resulting in photocontrol of voltage-gated Ca 2+ channels 116 or dendritic spine size [117] [118] [119] . Light control of CRY2 has been successfully used to inhibit G protein signalling in specific microdomains 120 and to control neurotransmitter release using an engineered botulinum neurotoxin 121 . In only a few examples have LOV or CRY2 domains been directly fused to the membrane protein itself, as demonstrated with K + channels 122 , tyrosine kinase receptors 123, 124 and AMPARs, to control their abundance at excitatory synapses 125 .
Chromophore-assisted laser inactivation. Genetically encoded fusion proteins can also be used in the CALI approach (Fig. 1b) , as tags to anchor photosensitive modules 126 or protein modules that directly act as singlet oxygen generators 127 . Bistability in azobenzenes, the ability for the cis and trans isomers each to be stable under particular illumination conditions and over long periods of time (minutes to days).
Photostationary state
The steady state reached by a photochemical reaction under a given illumination condition. in photo-isomerization, the photostationary state is usually given as a ratio of cis to trans photo-isomers.
Azologization
The process by which an established pharmacological compound is converted into a photoswitchable one, through the introduction of an azobenzene moiety.
Singlet oxygen
a specific state of the diatomic oxygen molecule (O 2 ) that is usually produced by light irradiation and that can cause photo-damage to nearby molecules. Activates GIRK channels in dark 55 Photo-affinity labels
Inactivates AMPA receptors in UV light
• Require chromophore delivery All methods -be they purely chemical, purely genetic or hybrid -have strengths and weaknesses; choosing one approach or the other depends on the biological problem at hand and on the genetic tractability of the target protein. 
Hybrid approaches
Hybrid approaches exploit chemical and genetic methodologies to precisely manipulate and control protein function with optochemical tools that are geneti cally anchored to, or incorporated into, the desired membrane target.
Unnatural amino acids. One hybrid strategy relies on unnatural amino acids (UAAs), which can be inserted at virtually any position into the target protein, including buried sites, using genetic code expansion 128 . This methodology hijacks the translational machinery through the reassignment of a stop codon (usually the amber stop codon), driven by a suppressor tRNA that is aminoacylated with the UAA of interest 129, 130 . Light-responsive UAAs are diverse in photochemical nature and have proved powerful tools to manipulate membrane receptors and ion channels 95, 131, 132 (Fig. 1c) . In particular, amber stop codon suppression was used to design nAChRs harbouring caged tyrosine 133, 134 and inwardly rectifying potassium channels incorporating caged cysteine 135 . As with diffusible caged compounds, the use of caged amino-acid side-chains enables time-controlled changes -abrupt and irreversible -in protein structure and function. UAAs that carry photocrosslinking or photoswitchable moieties have also been incorporated into various receptors and ion channels 95, 132 (see below). An advantage of photosensitive UAAs (and of UAAs in general) is that they can be inserted at any desired location in the target protein, including solvent-inaccessible sites, although UAA incorporation usually results in decreased protein expression 132 .
Photoswitchable tethered ligands. Photoswitchable tethered ligands (PTLs) provide another powerful and popular strategy to confer light responsiveness to receptors and ion channels. The approach relies on the covalent attachment of a photoswitchable ligand either at close proximity to its binding pocket, through a single cysteine substitution 136, 137 , or remotely, through bioconjugation to larger protein tags (as in the case of photoswitchable orthogonal remotely tethered ligands (PORTLs)) [138] [139] [140] . In both cases, different wavelengths of light are used to present or withdraw the pharmacologically active head group to or from its binding pocket (Fig. 1c) . Bi-anchoring chemical photoswitches (also known as nanotweezers or optotweezers) are additional optopharmacological tools that can control membrane proteins by evoking light-driven mechanical forces between two cysteine-substituted protein segments [141] [142] [143] (Fig. 1c) . a | With appropriate optopharmacological tools, light can be used to directly activate receptors or ion channels (as agonists), to inhibit them (as antagonists or negative allosteric modulators (NAMs)), or to positively modulate their function (as positive allosteric modulators (PAMs)). b | Activity of the target receptor or ion channel can be adjusted in a graded manner using different light intensities and/or wavelengths. The graph illustrates various levels of photo-antagonism associated with changes in light intensity or wavelength. c | Photomodulation of NMDA receptors (NMDARs) using photoswitchable amino acids (PSAAs) 164 . Left: chemical structures of a trans-PSAA and a cis-PSAA in the context of a protein. The azobenzene moiety is shaded in grey. Right, upper part: schematic representation of the mechanism of NMDAR photomodulation. The PSAA is incorporated in the GluN1 subunit (dark grey), close to the GluN2 subunit (light grey). GluN1 binds glycine (Gly ; purple), whereas GluN2 binds glutamate (Glu; red). Right, lower part: illumination with 365-nm light isomerizes PSAA to cis, a conformational change sufficient to destabilize glycine binding (that is, leading to a decrease in glycine affinity). This change results in a reduction of current amplitude (I) during agonist applications (left trace) and in an acceleration in deactivation kinetics upon glycine washout (right trace; current amplitude normalized (I norm )) over time (t). d | Photocontrol of kainate receptors (KARs) using photoswitchable tethered ligands (PTLs) 153 . Left: chemical structures of the PTL maleimide azobenzene glutamate (MAG) in the trans and cis configurations. The azobenzene moiety is shaded in grey. Right, upper part: schematic representation of heteromeric GluK2/K5 KARs. MAG is covalently attached to an engineered cysteine residue on the GluK2 subunit (light grey). Under 380-nm light, MAG adopts its cis configuration, allowing the glutamate moiety to dock in the agonist binding pocket. Right, lower part: heteromeric KARs conjugated with two PTLs can be directly activated with 380-nm light, which isomerizes the photoswitch to cis, and deactivated with 500-nm light, which reverts the photoswitch to trans (left trace). In such conditions, no or little desensitization is observed. By contrast, when two agonists (pale red) are pre-bound selectively to the GluK5 subunits, photoswitching leads to full receptor occupancy and almost complete receptor desensitization (right trace). Part c is adapted from reF. ◀ PTLs in the form of tethered photoswitchable azobenzene-coupled ligands have proved particularly efficient in photocontrolling neuronal receptors and ion channels 8, 17, 48, 49 . They are tripartite molecules, with a pharmacologically active head group and a cysteinereactive moiety (usually a maleimide), each substituted asymmetrically on opposite rings of a central photoreactive azobenzene chromophore (for example, see Fig. 2d ). The conjugation of the thiol group of the cysteine residue with maleimide is rapid (in a matter of minutes), highly selective and irreversible, enabling permanent installation of photoswitchable effectors on the protein target. Engineered light-controllable receptors and channels with PTLs include voltage-gated K + channels 136, 144 , two-pore domain K + channels 145 , iGluRs and mGluRs 137, 146, 147 The kinetics of photocontrol with PTLs are greatly accelerated, because PTLs are present in high local concentrations and cannot diffuse away 153 . Another advantage of such tethered ligands, when compared to freely diffusible photoswitches, is that they provide excellent separation in biological activity between the cis and trans forms. Thus, in the ideal realization, PTLs become truly binary photochemical switches for ion channels and receptors. The PTL approach also requires minimal modification (a single amino-acid substitution) of the target protein, limiting potential alteration of the target protein function. Perhaps the most distinctive advantage of PTLs for optical neurophysiology is that they provide control over receptors with subtype specificity.
For instance, the entire GABA A R family (containing subunits α1-α6) was made photocontrollable using the PTL strategy 150 . However, the PTL approach is probably restricted to sites that are accessible to the external solvent for proper protein conjugation, thus excluding intracellular and transmembrane protein domains.
Probing receptors and ion channels
Photoresponsive elements introduced at strategic locations in proteins or as ligands have been used to drive changes in protein structure and function with unsurpassed precision. All core biophysical features of receptors and ion channels -including ligand binding, activation and gating kinetics, and ionic permeation -can be controlled using optopharmacology. Light actuators can act as all-or-none switches, allowing direct channel opening or receptor activation, or as regulators, modulating the activity of receptors or ion channels that are activated by their cognate stimuli (Fig. 2a) . Therefore, light can mimic agonists (full, partial or inverse), antagonists (competitive or noncompetitive), channel blockers and openers, or negative or positive allosteric modulators (NAMs or PAMs). The use of different light intensities and/or wavelengths to elicit graded effects on receptor or ion channel function confers another level of refined control of the protein target (Fig. 2b) .
Mapping structural properties
Photo-affinity labelling with photocrosslinking ligands (Fig. 1a) has been used extensively to map ligand binding sites on receptors and channels at atomic resolution 16, 95 . This chemical approach allows direct identification of the amino-acid residues that contribute to a ligand binding site without a priori knowledge of the site of interaction. Examples of sites mapped using this technique include the agonist-binding sites of nAChRs 16 162 or potentiated 163 states of NMDA receptors (NMDARs). Generally, the irreversible nature of photocrosslinking enables the accumulation of trapped proteins in a given conformational state, resulting in strong functional phenotypes. 
Agonist deactivation kinetics
Current decay following agonist removal from a ligand-gated ion channel.
Controlling channel properties
Azobenzene-based photoswitchable UAAs (PSAAs) provide alternative means to photocontrol the biophysical attributes of target proteins. The introduction of PSAAs within different NMDAR subunits and domains has enabled rapid, reversible and allosteric regulation of channel-open probability, agonist sensitivity and deactivation kinetics (Fig. 2c) , as well as modulation of ionic conductance and Mg 2+ pore block 164 , without directly interfering with natural gating mecha nisms. In that respect, PSAAs differ from most PTLs, which instead act as surrogate receptor agonists 137 and abolish the need for natural agonist activation. Thus, in native settings, PSAAs can preserve natural patterns of receptor activation, whereas PTLs can take over immediate control of receptor activation and signalling. As examples, fast photoswitching using PTLs enables synaptic activation profiles to be mimicked 147 , whereas tuning agonist deactivation kinetics using PSAAs 164 could be useful to assess how this gating parameter sculpts the time window for synaptic plasticity and integration.
Pushing photocontrol even further, photoswitchable nanotweezers, which covalently attach to two engineered cysteine residues, fully substitute for the natural gating machinery of channels by triggering forceps-like mechanical forces on transmembrane helices upon azobenzene isomerization. This technology enables direct light-dependent opening and closure of ligandgated ion channels such as P2X receptors 141, 142 or acidsensing ion channels (ASICs) 141 . Optotweezers of various sizes also provide useful molecular rulers to probe the conformational rearrangements involved in pore dilation and the control of ion fluxes 142, 143 .
Temporal and molecular precision
Generally, optopharmacology offers tools of great temporal and spatial precision for the biophysical study of receptors and channels.
Caged agonists permit rapid ligand delivery (<25 µs), which is useful for probing receptor onset kinetics 22, 25, 38, 165, 166 . Similarly, fast light switching using PTLs allows submillisecond control of ligand binding and unbinding 153 , surpassing the temporal resolution of conventional techniques for studying receptors and channels, which are based on mechanical fastperfusion systems and are limited by issues related to ligand diffusion.
Accurate targeting of individual subunits is also achievable using optopharmacology. Using PALs as agonist analogues, the contribution of sequential binding events to channel gating in multimeric complexes can be dissected, as has been demonstrated with tetrameric cyclic-nucleotide-gated channels 92 . Similarly, using PTLs conjugated to specific subunits, the influence of individual subunit occupancy on receptor gating can be resolved, as has been achieved for homomeric and heteromeric iGluRs 153 ( Fig. 2d) and mGluRs 167 . Small single crosslinking groups and azobenzene groups appear to be remarkably efficient photo-devices for gaining real-time control of large molecular complexes and their functionalities.
Interrogation of neuronal physiology
Optopharmacology has opened new windows for understanding neuronal physiology by allowing the control of ion channels and receptors in locations that are poorly accessible to electrophysiological or pharmacological manipulations, such as subcellular compartments or presynaptic and postsynaptic sites. Caged neurotransmitters, especially caged glutamate and GABA, were the first photochemical tools to have major impacts on neurobiology 19, 168 . Neurotransmitter uncaging has two important advantages for neuronal physiology. First, the kinetics of release are very rapid (on a submillisecond timescale) 22, 25, 38 and can mimic the time course of presynaptic neurotransmitter release. Second, the measured downstream effects bypass (and therefore are unambiguously dissociated from) upstream signal production. Hence, laser-mediated uncaging enables stereotyped input to be applied at will to any brain region or part of a neuron in a highly reproducible manner 168, 169 . Glutamate uncaging can also produce connectivity maps between nearby or even distant neurons 169, 170 -a task that is nowadays routinely achieved using channelrhodopsin 10 .
Trafficking and compartmentalization
Our understanding of how ion channels and receptors traffic and compartmentalize in neurons has greatly benefited from optopharmacological techniques. Specific receptors and ion channels can be manipulated or isolated in a compartment-specific manner using appropriate photoresponsive ligands and patterns of illumination 88 . Two-photon uncaging of glutamate or GABA permits functional mapping of neurotransmitter receptor locations and densities with individual-spine resolution 28, 171 . Glutamate-uncaging experiments in brain slices have revealed that the expression of functional AMPARs is tightly correlated with spine size and geometry in pyramidal neurons, with mushroom spines containing the largest numbers of receptors 23 (Fig. 3a) .
6-Azido-7-nitro-1,4-dihydroquinoxaline-2,3-dione (ANQX), a PAL that irreversibly antagonizes surface AMPARs, was used to investigate the trafficking of native AMPARs; this approach revealed that AMPAR . Receptor activity is revealed using whole-cell patch-clamp recordings in voltage-clamp mode. b | Compartment-specific blockade of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels using the photoswitch acrylamide azobenzene quaternary ammonium (AAQ) 173 . Left: chemical structures of trans-AAQ and cis-AAQ. Middle: schematic representation of photoreversible HCN blockade using AAQ. Right: probability of spiking is increased when HCN channels are blocked in the axon initial segment (AIS), but decreased when these channels are blocked in the soma 173 . Neuronal excitability is measured using whole-cell patch-clamp recordings in current-clamp mode. c | Single-spine structural long-term potentiation (LTP) induced using 2P uncaging of glutamate 24 or 1P activation of light-controllable NMDA receptors (LiGluNs) expressed in transfected neurons (purple) 147 . The left and middle cartoons show how illumination leads to glutamate receptor activation and calcium entry into the spine, whereas the right cartoon depicts the resulting long-lasting changes in dendritic spine morphology. The graph on the right illustrates the evolution of the spine volume as a function of time before and after glutamate uncaging (denoted by arrow). I, current amplitude; t, time; V m , membrane potential. Part a is adapted from reF.
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, part b is adapted from reF. 173 and part c is adapted from reF.
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◀ NATuRE REvIEwS | NeuROscieNce insertion at synapses occurs primarily through lateral diffu sion from extrasynaptic sites 93 . Subcellular mapping of receptors using two-photon uncaging and subunitspecific PTLs also revealed that α5-subunit-containing GABA A Rs are distributed evenly along dendrites of CA1 pyramidal neurons, whereas α1-subunit-containing GABA A Rs are concentrated at (inhibitory) synapses 150 . In the same neurons, no current was detected following local uncaging of nAChR agonist, whereas large responses were detected on nearby CA1 interneurons, mostly at perisomatic sites 172 . Similar experiments performed in the medial habenula showed that in addition to concentrating close to (or at) the soma 35 , nAChRs also populate axons 36 , raising questions about the source of acetylcholine and its physiological role. In the axon initial segment (AIS) of gerbil auditory neurons, the contributions of specific ion channel conductances to neuronal firing were dissected using acrylamide azobenzene quaternary ammonium (AAQ) as a light-sensitive channel blocker. Hyperpolarization and cyclic-nucleotide-gated channels located in the AIS, but not in the soma or dendrites, were found to strongly influence excitability by controlling spike threshold and probability 173 ( Fig. 3b ). In comparison with other methods that enable the mapping of biomolecules with subcellular resolution (for example, electron microscopy or immunolabelling), optopharmacology has this essential advantage of informing about the functional effects of target compartmentalization and engagement.
Investigation of spine and dendritic function
Spine and dendritic function has been studied extensively using two-photon uncaging of glutamate 20 . Although the z-resolution of two-photon uncaging (~1.6 µm) is not high enough to resolve a single spine head, laser light power can be tuned such that the currents evoked by the photolysis of caged compounds are the same as those from a single quantum release of neurotransmitter 23 . The direction of 60 such photochemical quanta at a small spine at 1-2 Hz induced structural LTP that lasted more than 90 minutes 24 (Fig. 3c) . Coupling two-photon uncaging with genetically encoded fluorescence indicators has enabled the imaging of AMPAR insertion associated with structural LTP 174 , the local lifetime of activation of Ca 2+ /calmodulin-dependent protein kinase II 175 , the spread of RAS induced by LTP 176 , the role of RHO during LTP 177, 178 and long-distance ERK signalling 179 (for a review, see reF. 180 ). Directly photoagonizing synaptic light-sensitive NMDARs (LiGluNs) using PTLs induced structural LTP at single spines 147 ( Fig. 3c) , whereas photo-antagonizing LiGluNs following glutamate uncaging prevented such LTP, demonstrating that caged compounds and PTLs can be used together 147 . Although one-photon uncaging has contributed to our understanding of dendritic integration 181 , twophoton uncaging at many individual spines along dendritic segments has revealed a new level of detail by showing that forward-propagating dendritic spikes can be initiated by as few as 20 synchronous quanta (release events) on the same dendritic branch 182 . Pairing twophoton calcium imaging with two-photon glutamate uncaging at single and multiple spines has also enabled detailed study of Ca 2+ dynamics. For example, spines with large necks were found to allow greater Ca 2+ efflux into the dendritic shaft, and consequently showed smaller Ca 2+ increases inside the spine than did spines with small necks 183 . Moreover, the sequence in which excitatory synapses along a single dendrite are activated was found to be crucial for controlling the size of the local Ca 2+ signal and determining how neurons respond 184 , confirming an old hypothesis of directional selectivity 185 .
Control of synaptic physiology
Synaptic physiology can also be controlled with cell-type and microdomain specificity using genetic and hybrid approaches. For example, photoinactivation of soluble N-ethylmaleimide-sensitive factor-activating protein receptor (SNARE) proteins fused with genetically encoded singlet oxygen generators fully disrupted presynaptic vesicular release at targeted synapses in a spatially and temporally precise manner in rat hippocampal slices and in behaving Caenorhabditis elegans 127 . This approach -known as inhibition of synapses with CALI -targets synaptic proteins, and therefore has a broad applicability in understanding the contributions of individual synapses to the control of neural circuits and behaviours.
PTLs and opto-XRs have the potential to be used to probe the roles of receptors and ion channels in distinct synaptic compartments (including presynaptic, postsynaptic and extrasynaptic compartments) and in a cell-type-specific manner (Fig. 4) . For example, a retrograde signal that enhances recovery from presynaptic depression was revealed at the Drosophila neuromuscular junction upon specific photoactivation of postsynaptic light-controllable kainate-type glutamate receptors (LiGluRs) 186 . The probability of neurotransmitter release, and thereby short-term plasticity, can also be precisely manipulated optically via presynaptically expressed light-sensitive mGluR2 (LimGluR2) in hippocampal neurons 146 ( Fig. 4a) . Synaptic and extrasynaptic GABAergic inhibition was independently controlled using α1-subunit and α5-subunit-containing isoforms of lightsensitive GABA A Rs (LiGABARs), respectively, providing means to evaluate the impact of phasic versus tonic inhibition in a neural circuit 150 (Fig. 4b) . Similarly, NMDARmediated currents can be precisely controlled at synapses using specific isoforms of LiGluNs. In organotypic hippocampal slices, the photo-antagonism of GluN2A-containing LiGluNs during LTP induction is sufficient to reversibly prevent morphological and functional changes, enabling 'time-locked' gating of LTP 147 . Finally, glial cell activity and gliotransmission have also been manipulated using PTLs. Exploiting the relatively high conductance and Ca 2+ permeability of LiGluRs, light-evoked Ca 2+ elevations in cultured cortical astrocytes were shown to trigger non-vesicular release of glutamate 187 , demonstrating the utility of LiGluR-mediated optopharmacological approaches for studying electrically silent cells (Fig. 4c) .
Multi-chromophore approaches
Synthetic chromophores offer the potential for flexible manipulation of wavelength absorption through spectral tuning, which is exploited in the confocal imaging of multiple colours without channel crosstalk. Pairing
Directional selectivity
The ability of a neuron to respond differentially to the direction of the stimulus.
Gliotransmission
The transmission of a signalling molecule that is released from glial cells and that acts on nearby cells (such as neurons).
www.nature.com/nrn two-photon uncaging of glutamate at 720 nm with bluelight activation of channelrhodopsin 2 (ChR2) enables all-optical induction of structural LTP 188 , as caged glutamate does not absorb blue light, whereas ChR2 is hardly activated by 720-nm light at all. Another strategy is to pair a blue-light-sensitive caged GABA with two-photon glutamate uncaging, which takes advantage of the quasiabsence of GABA uncaging at 720 nm. Glutamate and GABA signalling at single spines, and how they influence each other, has been probed using this approach 189, 190 . An elegant study using two-colour actuation paired circuitspecific expression of ChR2 in dopamine neurons with two-photon uncaging of glutamate on dopamine 1 receptor (D1R)-expressing neurons to determine the temporal window of the effects of dopamine on singlespine plasticity in the nucleus accumbens 191 . Recently, a new caging chromophore has been developed that enables the photochemical control of several important signalling molecules, including glutamate 192 , GABA 193 and cyclic nucleotides 194, 195 , with excellent chromatic independence, enabling two-colour uncaging and actuation with various wavelengths of light 196 . Moreover, taking advantage of the broad spectral properties of photoswitches, as well as orthogonal strategies for their attachment, multiple receptor subpopulations can now be simultaneously and independently manipulated (through so-called multiplexing) 138, 139 . This advance opens interesting perspectives for studying potential crosstalk between different neurotransmitter systems.
In vivo optopharmacology
One fundamental goal of modern neuropharmacology is to causally link changes in receptor activity in given neuronal pathways with alterations of circuit physiology and ultimately of behaviour. The utility of classical pharmacology in vivo in achieving this goal is limited, because local drug delivery is slow, imprecise and hardly compatible with electrophysiology. By contrast, optochemical technologies are, in principle, able to mimic the timing, amplitude and spread of naturally occurring . Photoantagonizing LimGluRs with 380-nm light decreases neurotransmitter release and postsynaptic currents (bottom traces). b | Optical control of postsynaptic and extrasynaptic currents. Phasic (synaptic) and tonic (extrasynaptic) GABA type A receptor (GABAR)-mediated inhibitory currents (bottom traces) can be photo-antagonized under 380-nm light by using α1-subunit and α5-subunit-containing light-inhibitable GABARs (LiGABARs), respectively 150 . c | Optical control of gliotransmission using light-activatable glutamate receptors (LiGluRs) expressed in astrocytes 187 . When LiGluRs are activated with pulses of 380-nm light, the intracellular calcium concentration increases (bottom trace), triggering nonvesicular release of glutamate. ΔF/F, changes in calcium-dependent fluorescence; I, current amplitude; iGluR , ionotropic glutamate receptor ; mGluR , metabotropic glutamate receptor ; t, time. Part a is adapted from reF.
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NATuRE REvIEwS | NeuROscieNce modulatory signals. In addition, the advent of in vivo optogenetics in the past decade 10 has pushed advances in complementary technologies, such as multimodal fibres that enable optical, electrical and chemical interrogation. Such technologies can locally deliver light and chemicals in precisely defined brain regions, while simultaneously recording neuronal activity 197, 198 . Controlling the brain's own receptors and channels with light in the behaving animal is thus now in reach.
Small organic, diffusible photochemicals have profoundly affected neurophysiology research in vitro (see above), but they come with one major, inherent drawback when it comes to in vivo applications: they must be supplied continuously. In frog tadpoles or fish larvae, photoswitch application and photocontrol are relatively easy, because these animals are transparent and the photoswitch can simply be added to the swimming water 66 . For example, diffusible opto-PAMs and opto-NAMs of mGluRs [66] [67] [68] and photoswitchable activators of GIRK channels 55 drove light-dependent motility behaviour in zebrafish larvae, and a rhodamine-based photocontrollable transient receptor potential A1 agonist (optovin) drove rapid and reversible motor activity in paralysed zebrafish 199 . Similarly, the behaviour of C. elegans fed with photoswitchable ligands of nAChRs could be light-dependently perturbed 63 . The reliable and quantitative application of diffusible photochemicals in the nervous tissue of rodents is more challenging. However, proof of concept for in vivo twophoton glutamate uncaging has been demonstrated 200 . Two-photon uncaging of caged glutamate applied to the pial surface led to the stimulation of single spines in superficial cortical layers (assessed using calcium imaging and patch-clamp recordings). The concentration of caged glutamate was estimated to be approximately homogeneous up to 200 µm below the surface, and the synaptic effects observed in vivo confirmed previous reports from brain slices 23 . The feasibility of controlling neuromodulatory mechanisms in freely behaving rodents using diffusible photochemicals was recently further demonstrated using photosensitized mGluR-targeting drugs that either were 'azologized' 68, 69 or contained a protecting group that was released on exposure to light 201 . Unlike other small non-tethered photochemicals, which often have diffusion-related issues, quaternary ammonium photoswitchable blockers (including AAQ, quaternary ammonium azobenzene quaternary ammonium (QAQ) and benzyl ethyl aminoazobenzene quaternary ammonium (BENAQ)) 45, 50, 52, [202] [203] [204] [205] cross membranes and accumulate within cells, where they block voltagegated ion channels and can photosensitize neural tissue for days after a single infusion 203 . Such long-lasting photosensitization of neurons restored visual functions in blind mice 206 and controlled pain signalling in rats 52 . Another alternative to mitigate diffusion issues is to immobilize the photochemical near its target receptorfor example, using an antibody-based CALI approach. The latter strategy, using specific eosin-conjugated antibodies delivered locally to the hippocampus or the lateral habenula, irreversibly inactivated GluA1-containing synaptic AMPARs, resulting in light-induced erasure of contextual fear memory 98 or avoidance learning 207 , respectively.
The most straightforward means of limiting diffusion is to have the photochemical contained within (or anchored to) the membrane protein itself, as in genetic methods. Ideally, the engineered receptors should be controllable with kinetics that mimic those of neuronal excitability and transmission, while preserving the properties of endogenous receptors (including sensitivity to endogenous stimuli, coupling to signalling pathways, expression patterns and levels, subcellular trafficking and recycling, and so on). In practice, these requirements have proved difficult to combine. For instance, opto-XRs, which contain a naturally occurring retinal group in their agonist-binding pocket, are insensitive to their cognate ligands 102, 103, 106 . Hence, opto-XRs cannot fully replace endogenous receptors and must be ectopically expressed. This results in a mixture of exogenous and endogenous receptor populations, which may potentially compete for subcellular targeting 109 or express at non-physiological levels.
Nonetheless, opto-XRs have proved useful for triggering specific intracellular GPCR signalling pathways with high spatial and temporal precision (Fig. 5a) . Photoactivation of light-controllable β2-adrenergic receptors (opto-β2ARs) expressed in principal neurons of the basolateral amygdala modulates neuronal activity and induces anxiety-like behavioural states 103 . Importantly, these opto-β2ARs show signalling (in terms of cAMP production and MAP kinase activation) and dynamics (for example, internalization) similar to the characteristics of endogenous β2ARs. Likewise, lightcontrollable µ-opioid receptors (opto-MORs) closely match wild-type MORs in terms of signalling and trafficking and can promote opposite behavioural responses (reward or aversion), depending on their location in the brain 106 . Placing the C-terminal domain of the serotonin receptors 5-HT 1a R or 5-HT 2c R onto vertebrate opsins yields chimeric opto-5-HTRs that signal and distribute at the subcellular level like their wild-type counterparts 110, 111 . Activation of these chimeric receptors in the dorsal raphe nucleus of awake mice reveals reduced anxiety, although via different, subtype-dependent mechanisms. In general, opto-XRs provide valuable optomolecular tools to study signalling cascades in vivo, although the question of how well their activation mimics that of endogenous receptors remains unsettled.
In hybrid approaches, single-cysteine or single-UAA substitutions only minimally perturb target proteins. Hence, the modified receptor or ion channel usually behaves like its wild-type counterpart (for example, its sensitivity to endogenous neurotransmitters is unaffected) but is photocontrollable 147, 150, 208, 209 . Nevertheless, implementing hybrid approaches to study brain proteins in animals has been challenging, because of the dual requirement for gene delivery and photochemical delivery (Fig. 5b) . PTLs attached to glutamate receptors via an engineered cysteine were initially introduced into zebrafish larvae 210 , and several studies since then have reported the use of this LiGluR technology in behaving zebrafish 146, 147, 211, 212 . In mice, the PTL approach was originally implemented in the eye -a compartmentalized organ www.nature.com/nrn with ideal access to light and for drug delivery 213 -with the aim of restoring visual function 214, 215 . In most of these studies, however, LiGluRs were utilized as binary on-off switches of action potential firing, as in classical optogenetics, and not to interrogate receptor function. An arsenal of light-activatable and light-inhibitable iGluRs and mGluRs of various subtypes are available 17, 49 , but they remain to be fully exploited in vivo to understand how different GluR subtypes contribute to neural circuit operation and behaviour. Studies using LiGluNs in zebrafish that highlighted the role of GluN2A-containing receptors in the formation of sensory topographic maps have set a precedent for this kind of work 147 . Cysteine-anchored PTLs have been deployed in the mouse brain in vivo -first in superficial cortical layers, using LiGABARs 150 and LiGluRs 208 , and more recently in deep brain areas and behaving mice, using light-controllable nAChRs (LinAChRs) 209 . Importantly, although free cysteines are present at other extracellular sites on cells, this approach to photosensitizing receptors has proved to be remarkably specific in both fish and mice, with wild-type neurons or animals being unaffected by light after PTL treatment 146, 150, 208, 209 . Photoswitches can be applied topically to the cortex after craniotomy and duratomy, but to be targeted deeper in the brain they must be infused locally using cannulae. Systemic application of photoswitches would probably be problematic, owing to the strong lability and widespread reactivity of the maleimide group, but recently developed self-labelling tags 138, 139 might show reduced off-target effects and fast degradation. Although the first generation of PTLs required near-UV light to operate, they could be efficiently photocontrolled up to 350 µm below the brain surface 150 . Recently developed red-shifted and two-photon-sensitive azobenzenes 84, [216] [217] [218] [219] should facilitate in vivo photocontrol with deeper-penetrating wavelengths of light.
Two options are available to express the mutated subunit for PTLs: viral expression and transgenic knock-in mice. A molecular replacement strategy using knockin animals is the optimal option in terms of ensuring unperturbed protein density and localization 150 . Although viral transduction is cheaper and quicker than transgenesis, expression levels may be altered (although not systematically; see reF. 147, 209 ). Nonetheless, viral transduction has one important added value, which is to afford circuit-specific targeting. For example, LinAChRs overexpressed in the ventral tegmental area (VTA) enabled acute and reversible inactivation of postsynaptic cholinergic transmission, leaving presynaptic nAChRs outside VTA afferents unaffected 209 (Fig. 5b) . Hence, LinAChRs could reveal, in real time, cholinergic tone in the VTA and its effect on VTA dopamine neuron firing in vivo 209 . By contrast, knock-in expression of light-controllable α1-subunit-containing GABA A Rs in mice enabled direct photocontrol of visually evoked responses and revealed the contribution of such receptors in shaping gamma oscillations in awake animals 150 . The abundance of PTL-labelled receptors is expected to decline over time, owing to constant protein turnover. However, experiments using LiGluRs indicate that this may not be a major issue for long-lasting behavioural assays. Indeed, light-mediated responses in LiGluR-expressing mice were maintained for 1 day 208 and up to 14 days 214 after a single bolus of photoswitchable ligand, demonstrating stable labelling and surface expression of the tagged receptors for prolonged periods of time.
The incorporation of photosensitive UAAs for in vivo studies of neuronal proteins remains in its infancy, although proof-of-concept experiments in various organisms, including rodents 135, [220] [221] [222] [223] , indicate that feasibility is in reach. In brain slices, a photo controllable inwardly rectifying potassium (Kir2. 206, 226 . light delivered at the appropriate wavelength and intensity could potentially trigger signals at specific times and places and with an accurate dosing pattern, thereby reducing off-target effects. This concept has shown promise in animal models for two neurological applications: vision restoration and pain management.
Vision restoration
Degenerative retinal diseases are characterized by progressive loss of photoreceptors, ultimately leading to blindness. one therapeutic strategy for advanced retinal degeneration, after photoreceptors have been lost completely, is to photosensitize the remaining retinal neurons. Photoswitchable blockers of voltage-gated ion channels 45, [50] [51] [52] have been tested for their ability to photosensitize the blind retina in animal models of retinal degeneration [202] [203] [204] [205] 227 . The first generation of these agents elicited robust light responses in blind retinas ex vivo, and restored the pupillary light reflex and light-avoidance behaviour in blind mice 202 . Newly developed, improved photoswitches that fully operate in the visible spectrum and that quickly relax back to trans in darkness were later designed, eliminating the need for two different wavelengths of light (including potentially damaging uv light) for on and off control. These molecules photosensitized blind retinas from mice and rats [203] [204] [205] and restored visual fear conditioning in blind mice 203 . A single intraocular injection of a low-micromolar solution containing a photoswitch named benzyl ethyl aminoazobenzene quaternary ammonium (BENAQ) photosensitized blind retinas for almost a month 205 . Interestingly, certain photoswitches do not photosensitize all retinal neurons indiscriminately 204 , and therefore permit the restoration of complex visual processing in the blind retina, such as ON and OFF responses 227 .
Completely restoring visual functions may still require cell-specific targeting of retinal neurons -for instance, using optogenetic gene therapy. A phase I/II clinical trial of channelrhodopsin 2 for advanced retinitis pigmentosa is currently underway 228, 229 . Meanwhile, other optogenetic technologies based on engineered mammalian receptors, which may be less immunogenic, are being preclinically evaluated. The expression of light-activatable glutamate receptors (liGluRs; red-shifted versions included) in retinal ganglion cells or oN-bipolar cells restored light sensitivity to blind retinas from mice and dogs 213, 214 . A combination of two orthogonal systems, liGluR and SNAG-metabotropic glutamate receptor 2 (mGluR2; a light-controllable mGluR with a remotely tethered photoswitch), improved oN and oFF responses and enhanced visual acuity 215 . Finally, the mGluR-melanopsin chimera opto-mGluR6, which, unlike liGluRs, does not require photoswitch delivery, is another interesting alternative strategy that restored oN responses in blind mouse retinas with moderate light levels 107 .
Pain management
Many ion channels and receptors expressed centrally or peripherally are involved in nociception 230 and represent obvious targets for focused and phototitrated analgesia. Photocontrollable drugs potentially useful for controlling pain signalling include transient receptor potential v1 (TRPv1) channel agonists and antagonists 58, 231 , TRPA1 channel agonists 199 , μ-opioid receptor agonists 232 , GABA type A receptor potentiators 71 , blockers of voltage-gated Na + channels 52, 233 and mGluR modulators [66] [67] [68] [69] 201 . Photochemical 41, 232 or optogenetic 106 regulators of opioid signalling could potentially provide analgesia at peripheral targets while avoiding brain pathways linked to addiction. Photoswitchable allosteric modulators of mGluRs -one an opto-positive allosteric modulator of mGluR4 (reF.
69
), and the other an opto-negative allosteric modulator of mGluR5 (reF.
68
) -provide photoreversible analgesia in behaving mice, at peripheral nerve endings and in the amygdala 68, 69 . Photoreversible local anaesthetics (namely quaternary ammonium azobenzene quaternary ammonium (QAQ) and quaternary ammonium aminoazo-benzene quaternary ammonium (QENAQ)) also demonstrated spatiotemporally precise and phototitrable control of pain signalling in behaving rodents 52, 233 . Notably, QAQ and QENAQ only enter and silence TRPv1 channel-expressing (that is, pain-sensing) neurons, minimizing undesirable off-target effects on other sensory neurons.
Outlook
A major hurdle for implementing optopharmacology in clinical settings is light delivery to precise locations in the body, the eye being an obvious exception. Recent advances in preclinical developments have generated light delivery devices that are miniaturized, injectable, programmable and wirelessly controlled, affording efficient remote photocontrol and minimal damage to neural tissue [234] [235] [236] [237] [238] . Concomitant local drug delivery is also possible with wireless opto-fluidic probes that combine a micro-light-emitting device (lED) with soft microfluidic delivery systems 239 . In parallel, photochemicals that respond to deeper-penetrating red or infrared light 84 have been developed, possibly eliminating the need for lED implantation in some potential applications. Despite rapid technological advances, optopharmacological approaches are still far from ready to use in the clinic. Tolerability and reduced invasiveness (to liberate the recipient's mobility) remain important challenges for clinical success.
www.nature.com/nrn a caged cysteine in the channel pore region was successfully expressed in the mouse neocortex 135 , allowing acute light-induced suppression of neuronal firing. With its abilities to be genetically encoded and to target different sites of the target protein, UAA-based photocontrol combines several advantages; however, the system requires multiple components to be delivered -including the orthogonal tRNA-synthetase pair and the mutant target protein of interest -so its implementation in vivo is technically difficult. The bioavailabi lity of the UAA poses another hurdle. Recent successful attempts to address these challenges include the generation of transgenic mice carrying the genes that encode the necessary tRNA and synthetase needed for amber stop codon suppression 221, 223 . In principle, photoresponsive UAAs provide flexible means not only for optical control of protein activities but also for the identification of interacting partners within signalling complexes (using photocrosslinking UAAs 95 ).
Concluding remarks and perspectives
With its high flexibility and versatility, optopharmacology has yielded a large repertoire of light-tunable ligands, ion channels and neurotransmitter receptors, allowing fast and remote control over specific neuronal signalling pathways at specific locations within a cell, a network or an organism. By establishing causal relationships between a protein activity and a cellular or behavioural output, optopharmacology seems unrivalled in its potential to unlock molecular logic in the brain. It also holds strong potential for identifying new therapeutic targets in neurological disorders (bOx 1). It can also be used to explore the role and signalling mechanisms of numerous receptor and ion channel subtypes in their natural environment in normal and diseased states. Virtually any protein, membrane-associated or soluble, is amenable to optopharmacological engineering, provided that its activity is controllable by interacting ligands or binding partners. In that respect, ion channel and receptor auxiliary subunits, which usually do not harbour clearly defined pharmacological sites, seem to be less tractable for optopharmacological engineering than principal or pore-forming subunits. Generally, the greatest molecular specificity can be obtained from lightactivated chemicals that are tethered to specific proteins (such as PTLs). By contrast, approaches that rely solely on synthetic ligands (such as caged compounds and photoswitchable ligands) have the major advantage of not requiring genetic modifications of the target protein.
Both approaches require synthetic chemistry, however, which can be arduous and costly. Naturally occurring photosensitive proteins, usually from plants or microorganisms, that bypass the need for chemical synthesis offer an alternative. They can be easily spliced onto mammalian proteins, enabling light-control of intracellular or cell-surface proteins. The current boom in the genome sequencing of various organisms (including nonanimal organisms) augurs bright days for biotechnological applications that use native light-sensitive modules. Neuroscience should greatly benefit from advances in optogenetics and optopharmacology. However, one serious limitation remains to implementing light-based approaches in behaving animals: the delivery of light to the cells of interest often requires invasive surgery. Novel approaches that are based on transcranial acoustic 224 or magnetic 225 stimulation to remotely manipulate neurons and biochemical pathways may overcome this hurdle, yet they face many other technical obstacles. Methods to illuminate nervous tissues with reduced invasiveness are also emerging, with some even bypassing the need for surgery (bOx 1). Light-based approaches such as optopharmacology will undoubtedly continue shaping new horizons in tackling fundamental processes in brain physiology and pathology.
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